Measurements across the four peptides
Before two results can be compared, they need to be measuring the same thing. These often are not.
Area, proportion, weight and tissue response
The liver scan began this site’s argument, but a scan can report several different quantities. Visceral-fat area describes a cross-section of fat around organs. Liver-fat proportion describes fat within liver tissue. Body weight includes much more than either compartment.
I want the unit to remain visible because it limits the claim in a useful way. The −42 cm² result for tesamorelin and the −82.4% relative liver-fat change for retatrutide cannot be sorted into “less” and “more” treatment effect. They have different denominators and came from different people.
| Study | Measured outcome | Study setting |
|---|---|---|
| Tesamorelin abdominal-fat trial | Visceral-fat area; treatment effect −42 cm² | 50 adults treated for HIV, six months |
| Retatrutide liver substudy | Relative liver-fat change; −82.4% in the highest-dose group at 24 weeks | 98 adults with overweight or obesity and MASLD, without type 2 diabetes |
| Retatrutide obesity trial | Body-weight change; −24.2% in the highest-dose group at 48 weeks | 338 adults |
| GHK-Cu collagen experiment | Collagen synthesis, with cell number unchanged | Human fibroblasts in culture |
| KPV colitis experiment | Recovery, inflammatory-cell infiltration and enzyme activity | Mice with induced colitis |
The human trial figures are group results. The culture and mouse findings concern their experimental models.
Community reports
The GHK-containing hair trial counted hairs in men receiving a combination preparation. A forum account of fuller-looking hair records a person’s impression under uncontrolled conditions. Those observations have different evidential weight, even when the vocabulary sounds similar.
Community accounts are anecdotal, not clinical evidence. They can suggest questions worth examining, but cannot establish a cause or the frequency of benefit and harm. Careful patient measurements could put those impressions beside observed outcomes; repeating the descriptions will not provide them.
Status and sample tests
Tesamorelin’s U.S. approval concerns excess abdominal fat in adults with HIV-associated lipodystrophy. Retatrutide remains investigational and unapproved. GHK-Cu has no approved drug indication, and KPV lacks an approved drug or dietary-supplement use. The compound pages describe the evidence in each setting.
Testing a sample asks another set of questions: identity, amount, unwanted chemicals, microbial contamination or endotoxins. A batch identifier and handling record connect the tested sample to the supply it is supposed to represent. A good result on one assay answers that assay’s question.
I favour measurements that retain their modesty. A precise result becomes more useful when its limits survive the retelling.